deferiprone has been researched along with Siderosis in 13 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Siderosis: A form of pneumoconiosis resulting from inhalation of iron in the mining dust or welding fumes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral deferiprone, a lipid-soluble iron chelator with ability to cross the blood-brain barrier, at a dose of 30 mg/kg per day was tested for safety in an open pilot study in 10 subjects with superficial siderosis." | 7.78 | Pilot safety trial of deferiprone in 10 subjects with superficial siderosis. ( Levy, M; Llinas, R, 2012) |
| "A man with superficial siderosis showed improvement in symptoms and reduction in hemosiderin by MR imaging following treatment with deferiprone, a lipid-soluble iron chelator." | 7.77 | Deferiprone reduces hemosiderin deposits in the brain of a patient with superficial siderosis. ( Levy, M; Llinas, RH, 2011) |
| "Cardiac events and death are not uncommon in adults with beta-thalassemia (b-TM) taking deferoxamine (DFO) monotherapy because of poor compliance and possibly the less effectiveness of DFO in controlling cardiac iron overload." | 7.76 | Cardiac events and cardiac T2* in Egyptian children and young adults with beta-thalassemia major taking deferoxamine. ( Abdin, IA; Ebeid, FS; El Safy, UR; Elalfy, MS; Ibrahim, AS; Salem, DS, 2010) |
| "Deferiprone monotherapy was significantly more effective than deferoxamine over 1 year in improving asymptomatic myocardial siderosis in beta-thalassemia major." | 6.72 | Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. ( Aessopos, A; Berdoukas, V; Galanello, R; Gotsis, ED; Karagiorga, M; Ladis, V; Pennell, DJ; Piga, A; Smith, GC; Tanner, MA; Westwood, MA; Wonke, B, 2006) |
| "We concluded that pregnancy is not a contraindication in beta-thalassemia major; complex individual care is needed to achieve a safe outcome for the mother." | 5.51 | A case of post-splenectomy transfusion-dependent homozygous beta-thalassemia major complicated with myocardial siderosis and osteoporosis and usage of iron-chelating therapy with deferiprone in pregnancy. ( Abu, MA; Ahmad, MF; Arsad, N; Chew, KT; Omar, MH; Shafiee, MN; Zakaria, NZ, 2019) |
| "In patients with severe myocardial siderosis and impaired LV function, combined chelation therapy with subcutaneous deferoxamine and oral deferiprone reduces myocardial iron and improves cardiac function." | 5.13 | Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. ( Agus, A; Dessi, C; Galanello, R; Nair, SV; Pennell, DJ; Pibiri, M; Smith, GC; Tanner, MA; Walker, JM; Westwood, MA, 2008) |
| "Fifteen postoperative patients with superficial siderosis were recruited, and seven patients were administered deferiprone (combination therapy group)." | 4.12 | Quantitative clinical and radiological recovery in post-operative patients with superficial siderosis by an iron chelator. ( Nose, Y; Sanjo, N; Sasaki, M; Tateishi, U; Uwano, I; Yokota, T, 2022) |
| "Cardiac events and death are not uncommon in adults with beta-thalassemia (b-TM) taking deferoxamine (DFO) monotherapy because of poor compliance and possibly the less effectiveness of DFO in controlling cardiac iron overload." | 3.76 | Cardiac events and cardiac T2* in Egyptian children and young adults with beta-thalassemia major taking deferoxamine. ( Abdin, IA; Ebeid, FS; El Safy, UR; Elalfy, MS; Ibrahim, AS; Salem, DS, 2010) |
| "Deferiprone monotherapy was significantly more effective than deferoxamine over 1 year in improving asymptomatic myocardial siderosis in beta-thalassemia major." | 2.72 | Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. ( Aessopos, A; Berdoukas, V; Galanello, R; Gotsis, ED; Karagiorga, M; Ladis, V; Pennell, DJ; Piga, A; Smith, GC; Tanner, MA; Westwood, MA; Wonke, B, 2006) |
| "We concluded that pregnancy is not a contraindication in beta-thalassemia major; complex individual care is needed to achieve a safe outcome for the mother." | 1.51 | A case of post-splenectomy transfusion-dependent homozygous beta-thalassemia major complicated with myocardial siderosis and osteoporosis and usage of iron-chelating therapy with deferiprone in pregnancy. ( Abu, MA; Ahmad, MF; Arsad, N; Chew, KT; Omar, MH; Shafiee, MN; Zakaria, NZ, 2019) |
| "Superficial siderosis is caused by recurrent haemorrhage in the subarachnoid space leading to haemosiderin deposition." | 1.39 | Treatment of superficial siderosis with iron chelation therapy. ( Baguley, D; Crundwell, G; Cummins, G; Lennox, G, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Nose, Y | 1 |
| Uwano, I | 1 |
| Tateishi, U | 1 |
| Sasaki, M | 1 |
| Yokota, T | 1 |
| Sanjo, N | 1 |
| Flores Martin, A | 1 |
| Shanmugarajah, P | 1 |
| Hoggard, N | 1 |
| Hadjivassiliou, M | 1 |
| Ahmad, MF | 1 |
| Zakaria, NZ | 1 |
| Arsad, N | 1 |
| Chew, KT | 1 |
| Abu, MA | 1 |
| Shafiee, MN | 1 |
| Omar, MH | 1 |
| Cummins, G | 1 |
| Crundwell, G | 1 |
| Baguley, D | 1 |
| Lennox, G | 1 |
| Huprikar, N | 1 |
| Gossweiler, M | 1 |
| Callaghan, M | 1 |
| Bunge, P | 1 |
| Schirinzi, T | 1 |
| Sancesario, G | 2 |
| Anemona, L | 1 |
| Pisani, A | 1 |
| Peng, CT | 1 |
| Chang, JS | 1 |
| Wang, LY | 1 |
| Chiou, SS | 1 |
| Hsiao, CC | 1 |
| Wang, SC | 1 |
| Hung, GY | 1 |
| Wu, KH | 1 |
| Levy, M | 2 |
| Llinas, RH | 1 |
| Elalfy, MS | 1 |
| Abdin, IA | 1 |
| El Safy, UR | 1 |
| Ibrahim, AS | 1 |
| Ebeid, FS | 1 |
| Salem, DS | 1 |
| Musallam, KM | 1 |
| Taher, AT | 1 |
| Llinas, R | 1 |
| Pennell, DJ | 2 |
| Berdoukas, V | 1 |
| Karagiorga, M | 1 |
| Ladis, V | 1 |
| Piga, A | 1 |
| Aessopos, A | 1 |
| Gotsis, ED | 1 |
| Tanner, MA | 2 |
| Smith, GC | 2 |
| Westwood, MA | 2 |
| Wonke, B | 1 |
| Galanello, R | 2 |
| Dessi, C | 1 |
| Agus, A | 1 |
| Pibiri, M | 1 |
| Nair, SV | 1 |
| Walker, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase IV Observational Study of Deferiprone (Ferriprox®) in the Treatment of Superficial Siderosis[NCT01284127] | 38 participants (Actual) | Observational | 2012-03-31 | Completed | |||
| A Randomized, Placebo Controlled, Double Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance[NCT00103753] | Phase 4 | 65 participants | Interventional | 2004-05-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for deferiprone and Siderosis
| Article | Year |
|---|---|
Treatment Response of Deferiprone in Infratentorial Superficial Siderosis: a Systematic Review.
Topics: Animals; Deferiprone; Hemosiderin; Humans; Iron Chelating Agents; Randomized Controlled Trials as To | 2021 |
2 trials available for deferiprone and Siderosis
| Article | Year |
|---|---|
Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.
Topics: Adult; beta-Thalassemia; Cardiomyopathies; Deferiprone; Deferoxamine; Female; Humans; Iron; Iron Che | 2006 |
Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.
Topics: Administration, Oral; Adult; beta-Thalassemia; Cardiomyopathies; Deferiprone; Deferoxamine; Drug The | 2008 |
10 other studies available for deferiprone and Siderosis
| Article | Year |
|---|---|
Quantitative clinical and radiological recovery in post-operative patients with superficial siderosis by an iron chelator.
Topics: Cerebellar Ataxia; Deferiprone; Humans; Iron Chelating Agents; Magnetic Resonance Imaging; Neurodege | 2022 |
A case of post-splenectomy transfusion-dependent homozygous beta-thalassemia major complicated with myocardial siderosis and osteoporosis and usage of iron-chelating therapy with deferiprone in pregnancy.
Topics: beta-Globins; beta-Thalassemia; Blood Transfusion; Cardiomyopathies; Deferiprone; Female; Homozygote | 2019 |
Treatment of superficial siderosis with iron chelation therapy.
Topics: Aged; Chelation Therapy; Deferiprone; Humans; Iron; Iron Chelating Agents; Male; Pyridones; Siderosi | 2013 |
Agranulocytosis with deferiprone treatment of superficial siderosis.
Topics: Aged; Agranulocytosis; Deferiprone; Humans; Iron Chelating Agents; Male; Pyridones; Siderosis | 2013 |
CSF biomarkers in superficial siderosis: a new tool for diagnosis and evaluation of therapeutic efficacy of deferiprone--a case report.
Topics: Aged; Deferiprone; Humans; Iron Chelating Agents; Male; Pyridones; Siderosis | 2014 |
Update on thalassemia treatment in Taiwan, including bone marrow transplantation, chelation therapy, and cardiomyopathy treatment effects.
Topics: Benzoates; beta-Thalassemia; Blood Transfusion; Bone Marrow Transplantation; Cardiomyopathies; Chela | 2009 |
Deferiprone reduces hemosiderin deposits in the brain of a patient with superficial siderosis.
Topics: Aged; Brain; Deferiprone; Hemosiderin; Humans; Iron Chelating Agents; Magnetic Resonance Imaging; Ma | 2011 |
Cardiac events and cardiac T2* in Egyptian children and young adults with beta-thalassemia major taking deferoxamine.
Topics: Adolescent; Age Factors; Benzoates; beta-Thalassemia; Child; Child, Preschool; Death; Deferasirox; D | 2010 |
Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia major.
Topics: beta-Thalassemia; Deferiprone; Heart Diseases; Humans; Iron Chelating Agents; Iron Overload; Magneti | 2011 |
Pilot safety trial of deferiprone in 10 subjects with superficial siderosis.
Topics: Adult; Aged; Brain; Deferiprone; Female; Hemosiderin; Humans; Male; Middle Aged; Pilot Projects; Pyr | 2012 |